These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23053307)

  • 1. Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM™.
    Casutt M; Konrad C; Schuepfer G
    Anaesthesist; 2012 Nov; 61(11):948-53. PubMed ID: 23053307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
    Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
    Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of laboratory coagulation tests and clotting factor levels on Rotation Thromboelastometry (ROTEM(R)) during major surgery with hemorrhage.
    Theusinger OM; Schröder CM; Eismon J; Emmert MY; Seifert B; Spahn DR; Baulig W
    Anesth Analg; 2013 Aug; 117(2):314-21. PubMed ID: 23780419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of rotational thromboelastometry, coagulation activation markers and thrombin generation assays in orthopedic patients during thromboprophylaxis with rivaroxaban and enoxaparin: a prospective cohort study.
    Oswald E; Velik-Salchner C; Innerhofer P; Tauber H; Auckenthaler T; Ulmer H; Streif W
    Blood Coagul Fibrinolysis; 2015 Mar; 26(2):136-44. PubMed ID: 25396759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the effect of factor Xa inhibitors on rotational thromboelastometry: a case series of bleeding patients.
    Mahamad S; Chaudhry H; Nisenbaum R; McFarlan A; Rizoli S; Ackery A; Sholzberg M
    J Thromb Thrombolysis; 2019 Feb; 47(2):272-279. PubMed ID: 30506352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bleeding during veno-venous ECMO cannot reliably be predicted by rotational thrombelastometry (ROTEM™).
    Hellmann C; Schmutz A; Kalbhenn J
    Perfusion; 2018 May; 33(4):289-296. PubMed ID: 29188749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Rivaroxaban Therapy on ROTEM Coagulation Parameters in Patients with Venous Thromboembolism.
    Chojnowski K; Górski T; Robak M; Treliński J
    Adv Clin Exp Med; 2015; 24(6):995-1000. PubMed ID: 26771971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
    Perzborn E; Heitmeier S; Laux V; Buchmüller A
    Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents.
    Dale BJ; Ginsberg JS; Johnston M; Hirsh J; Weitz JI; Eikelboom JW
    J Thromb Haemost; 2014 Nov; 12(11):1810-5. PubMed ID: 25196577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study.
    Körber MK; Langer E; Ziemer S; Perzborn E; Gericke C; Heymann Cv
    Clin Appl Thromb Hemost; 2014 Oct; 20(7):735-40. PubMed ID: 23832064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.
    Schenk B; Würtinger P; Streif W; Sturm W; Fries D; Bachler M
    Br J Anaesth; 2016 Nov; 117(5):583-591. PubMed ID: 27623677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma.
    Conversy B; Blais MC; Dunn M; Gara-Boivin C; Carioto L; del Castillo JR
    Vet J; 2013 Nov; 198(2):437-43. PubMed ID: 24053991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.
    Beiderlinden M; Werner P; Bahlmann A; Kemper J; Brezina T; Schäfer M; Görlinger K; Seidel H; Kienbaum P; Treschan TA
    BMC Anesthesiol; 2018 Feb; 18(1):18. PubMed ID: 29426286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.
    Hillarp A; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Lindahl TL
    J Thromb Haemost; 2011 Jan; 9(1):133-9. PubMed ID: 20946166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of point-of-care coagulation tests as alternatives to anti-Xa activity for monitoring the anticoagulant effects of rivaroxaban in healthy dogs.
    Lynch AM; Ruterbories LK; Griffith EH; Hanel RM; Stablein AP; Brooks MB
    J Vet Emerg Crit Care (San Antonio); 2021 Jan; 31(1):18-24. PubMed ID: 33118685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro reversal of supratherapeutic rivaroxaban levels with coagulation factor concentrates.
    Körber MK; Langer E; Kaufner L; Sander M; Von Heymann C
    Blood Transfus; 2016 Sep; 14(5):481-6. PubMed ID: 27177413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The in-vitro anticoagulant effect of rivaroxaban in neonates.
    Attard C; Monagle P; Kubitza D; Ignjatovic V
    Blood Coagul Fibrinolysis; 2014 Apr; 25(3):237-40. PubMed ID: 24418940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thromboelastographic evaluation of coagulative profiles in pig-to-monkey kidney xenotransplantation.
    Spiezia L; Boldrin M; Radu C; Bulato C; Bertini D; Bon M; Campello E; Vadori M; Galli C; Gavasso S; Nottle MB; Cowan PJ; Cozzi E; Simioni P
    Xenotransplantation; 2013; 20(2):89-99. PubMed ID: 23406330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban.
    Harenberg J; Marx S; Weiss C; Krämer R; Samama M; Schulman S;
    J Thromb Haemost; 2012 Jul; 10(7):1433-6. PubMed ID: 22947062
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.